Results 171 to 180 of about 24,245 (182)

Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial

Lancet Diabetes and Endocrinology,the, 2014
Mônica R Gadelha, Marcello D Bronstein, Thierry Brue   +2 more
exaly  

A Pituitary Society update to acromegaly management guidelines

Pituitary, 2020
Maria Fleseriu, Beverly M K Biller, Pamela U Freda   +2 more
exaly  

New therapeutic agents for acromegaly

Nature Reviews Endocrinology, 2015
Shlomo Melmed
exaly  

A Consensus on Criteria for Cure of Acromegaly

Journal of Clinical Endocrinology and Metabolism, 2010
Andrea Giustina, Philippe Chanson
exaly  

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

Lancet, The, 2001
Peter J Trainer, Ariel L Barkan, Laurence Katznelson   +2 more
exaly  

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

Journal of Clinical Endocrinology and Metabolism, 2014
Annamaria Colao, Maria Fleseriu
exaly  

Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities

Pituitary, 2017
Rosario Pivonello, Claudia Pivonello, Chiara Simeoli   +2 more
exaly  

Acromegaly: clinical features at diagnosis

Pituitary, 2016
Lucio Vilar
exaly  

Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly

Lancet, The, 2005
Aj Van Der Lely
exaly  

Growth Hormone Receptor Antagonists: Discovery, Development, and Use in Patients with Acromegaly

Endocrine Reviews, 2002
exaly